Apellis Pharmaceuticals sees schadenfreude stock boost as rival trial failsProactive Investors • 09/19/23
Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analystsMarket Watch • 09/19/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the FirmAccesswire • 09/17/23
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLSPRNewsWire • 09/16/23
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLSPRNewsWire • 09/16/23
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 09/12/23
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action LawsuitAccesswire • 09/11/23
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action LawsuitAccesswire • 09/11/23
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLSPRNewsWire • 09/09/23
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLSPRNewsWire • 09/07/23
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLSPRNewsWire • 09/02/23
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – APLSBusiness Wire • 08/31/23
APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire • 08/31/23
Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/30/23
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term SuccessGlobeNewsWire • 08/29/23
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc.(APLS) ShareholdersPRNewsWire • 08/28/23
APLS INVESTOR ALERT: Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitPRNewsWire • 08/26/23
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLSPRNewsWire • 08/25/23
APLS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Apellis Class Action LawsuitBusiness Wire • 08/24/23
Apellis Soars 28% After Identifying Potential Culprit Behind Eye Drug Safety WoesInvestors Business Daily • 08/23/23